Erosion of dosage compensation impacts human iPSC disease modeling. - Wikidata - awgldk - TriplyDB

Erosion of dosage compensation impacts human iPSC disease modeling.

Erosion of dosage compensation impacts human iPSC disease modeling.

http://www.wikidata.org/entity/Q36703082

about

Rapid single-step induction of functional neurons from human pluripotent stem cells Complexities of X chromosome inactivation status in female human induced pluripotent stem cells-a brief review and scientific update for autism research Function and evolution of the long noncoding RNA circuitry orchestrating X-chromosome inactivation in mammals White paper on guidelines concerning enteric nervous system stem cell therapy for enteric neuropathies Pluripotent Stem Cells: Current Understanding and Future Directions Induced Pluripotency and Gene Editing in Disease Modelling: Perspectives and Challenges Two Effective Routes for Removing Lineage Restriction Roadblocks: From Somatic Cells to Hepatocytes Using Patient-Derived Induced Pluripotent Stem Cells to Model and Treat Epilepsies Long noncoding RNAs in cell-fate programming and reprogramming Investigation of Rett syndrome using pluripotent stem cells A poor imitation of a natural process: a call to reconsider the iPSC engineering technique Human pluripotent stem cells for modelling human liver diseases and cell therapy Using human induced pluripotent stem cells to treat retinal disease From "directed differentiation" to "neuronal induction": modeling neuropsychiatric disease Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders A perspective on stem cell modeling of amyotrophic lateral sclerosis Overcoming the hurdles for a reproducible generation of human functionally mature reprogrammed neurons Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells Integrated Genomic Analysis of Diverse Induced Pluripotent Stem Cells from the Progenitor Cell Biology Consortium Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration Stem cells and modeling of autism spectrum disorders.Browsing (Epi)genomes: a guide to data resources and epigenome browsers for stem cell researchers.Solving the puzzle of Parkinson's disease using induced pluripotent stem cells.Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons.X Chromosome of female cells shows dynamic changes in status during human somatic cell reprogramming.Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons.Human stem cells for craniomaxillofacial reconstruction.Human germ cell formation in xenotransplants of induced pluripotent stem cells carrying X chromosome aneuploidies Xist deficiency and disorders of X-inactivation in rabbit embryonic stem cells can be rescued by transcription-factor-mediated conversion.Coupling of X-chromosome reactivation with the pluripotent stem cell state.Systematic identification of culture conditions for induction and maintenance of naive human pluripotency.Mutation frequency dynamics in HPRT locus in culture-adapted human embryonic stem cells and induced pluripotent stem cells correspond to their differentiated counterparts Genetic and epigenetic instability in human pluripotent stem cells.Human pluripotent stem cells: an emerging model in developmental biology.Epigenetic regulation of pluripotency and differentiation Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells.A modified TALEN-based system for robust generation of knock-out human pluripotent stem cell lines and disease models Stable X chromosome reactivation in female human induced pluripotent stem cells Brain white matter volume abnormalities in Lesch-Nyhan disease and its variants X chromosome inactivation: recent advances and a look forward.

P2860

Q26269862-7297B563-EFF5-4EB2-BE32-6756CE101DF6 Q26745947-06890ECB-DE41-4E41-805E-DCA6FC81354F Q26750257-611B5B71-C135-468A-AE13-700C77C5D9D7 Q26750556-9AF997C9-474E-4399-BF76-48248F1E5010 Q26769981-27C934F6-4CA3-4F30-A215-39EB12CEDB91 Q26775061-1779EE55-B65F-4118-A284-AFC5E60AF1DB Q26784188-E35AD49F-ED5F-4AC8-8939-FFD9C68008E7 Q26796332-91460E27-D437-40D0-A069-11D58174D1FE Q26822409-FBA99173-B046-438B-81C5-533B058C65DB Q26822991-3287EC92-1FF0-4F62-93CC-056B5F10BB1D Q26851933-E1ECC538-532B-4C2E-BB37-0B816D56740E Q27005360-C196751D-2EF7-425B-B5B5-7F906CD6AC83 Q27015087-D433DDA1-1E10-4531-BE00-C06EE124F726 Q27692698-51A04698-0453-40AA-9A84-503FC1A81EEC Q28080219-F1200FD9-438F-491B-BBE2-241D522E91E9 Q28080614-1E878222-B8BC-48B4-AFC8-041F26C96147 Q28083762-ED2E68AA-8167-4A28-84EB-9BE6576BAA97 Q28265816-DE229ACE-E01A-47F1-AE9E-4046C37FAF57 Q28596287-84EF6A8A-8D20-4E01-BC74-24BF3ECA0BC4 Q28649438-2AB8B6C3-4540-49FB-B051-A522B0A944C7 Q30401824-C010022D-5660-4C18-BA10-D15A35B228B4 Q30653491-C61E2759-3B11-4B3A-9A23-041B91652726 Q33358637-6311D873-0FF1-4968-8EEE-658749ADC768 Q33582775-6AF9B87E-14E4-4229-8CA5-8F1A9E927A2E Q33729692-37CC4194-A729-4787-9DC0-5DDF1947FDA9 Q33740090-A5AE3B75-5F79-4053-B3F6-7A89B30E089B Q33788845-AB039F4A-E7DC-4405-84F1-876BDF7E3601 Q34219813-68B0C12A-2F78-4775-9B75-4F237375BBAE Q34232250-D3D707D5-9998-4823-A549-19A5FE5C0FCF Q34266426-BD8F5DB0-E503-43DC-B627-8AB69AAB296C Q34288016-084D85B0-C425-4784-962E-104B7E520176 Q34294018-CA96B408-FD24-423B-A9B4-B5F299896732 Q34316491-60E47E73-3282-4953-A3CB-AEB1B9E537CA Q34325210-ADDC9708-167D-4A10-9333-557BA87F2092 Q34498966-EED004D0-CCD6-4968-B761-DB1C89A9FEA0 Q34845881-428A4F9F-BBB5-43D1-AA24-61C309534466 Q35037260-10400BA5-29D1-4D1E-B2FF-D6C7B4C21344 Q35075314-56B06D39-D1D9-4294-92BC-1953FE63432C Q35106500-F8AEE831-38C4-4625-97CA-C5813C96503F Q35116343-92B8AE39-592B-4776-AEF2-B4F9393592C0

P2860

Erosion of dosage compensation impacts human iPSC disease modeling.

http://www.wikidata.org/entity/Q36703082

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Erosion of dosage compensation impacts human iPSC disease modeling.

@ast

Erosion of dosage compensation impacts human iPSC disease modeling.

@en

type

label

Erosion of dosage compensation impacts human iPSC disease modeling.

@ast

Erosion of dosage compensation impacts human iPSC disease modeling.

@en

altLabel

Erosion of dosage compensation impacts human iPSC disease modeling

@en

prefLabel

Erosion of dosage compensation impacts human iPSC disease modeling.

@ast

Erosion of dosage compensation impacts human iPSC disease modeling.

@en

P1433

Q36703082-35F736F3-6B22-4383-8B85-A4A43DBA4FFB

P1476

Q36703082-2D3D20E8-D6A6-41CF-ADB2-DB4CA0717A80

P2093

Q36703082-1EA5138D-F231-4766-8171-F32A3E69B25C

Q36703082-85C5D702-2C7B-4936-B929-C0159798EFC6

Q36703082-9BC22B0B-000E-4551-84C2-88DBE5074CD7

Q36703082-ECA61DBB-7B9B-4A35-A138-BE1043DE3E6E

P2860

Q36703082-04D2B60D-834F-41E9-AE56-3BDD308D291F

Q36703082-0BEF3995-7FE3-4909-BA77-4DA41E897406

Q36703082-0DB9EC57-8B90-42AC-8A81-33E8B138182E

Q36703082-23BE89AB-6AE8-4026-8478-3A1B83457D2B

Q36703082-2736CCFF-F55A-425F-926B-218300FAC661

Q36703082-2EEE059E-1DEB-46AC-A8EB-1858239133EC

Q36703082-2F3B4495-1C1F-469C-BABF-BC7E97579960

Q36703082-37C7D094-E625-44BA-B2C0-A2CDDFBC63A9

Q36703082-3FC95987-1424-436F-A361-D66BBB2C47D4

Q36703082-4463D0BB-B6FA-4CF6-8E3B-B2CA3CC26F57

P304

Q36703082-820AEF34-F713-4713-81FB-D51A8930C1F0

P31

Q36703082-F0B4F809-40E1-4112-AE47-79C3B3DFA9D2

P356

Q36703082-F50480EC-2EE1-44AD-B546-197A04C0F9B0

P407

Q36703082-20712324-AA47-446C-B528-698A5D6E3350

P433

Q36703082-8D361E0F-62AD-4D32-AB5E-7DEC6BDC75F5

P478

Q36703082-4504F7FF-DBA9-4AD0-9618-978AD6BBF2A4

P50

Q36703082-3ECEF21D-111E-475F-A431-CF200C8E8E7A

Q36703082-F52E3365-5023-43DB-9DA3-50DF60A2BCAC

P577

Q36703082-EA090B66-66FE-4D88-88F9-B3DEB924624F

P5875

Q36703082-4DD145B2-7327-423D-B772-A1538960B82C

P698

Q36703082-AC9BB950-9BF0-4DE3-ACCA-AF54C82458D7

P932

Q36703082-F2DB1AF6-981F-4409-8AC7-DD26441B9312

P356

J.STEM.2012.02.014

P1433

P1476

Erosion of dosage compensation impacts human iPSC disease modeling.

@en

P2093

A Sophie de Boer

http://www.w3.org/2001/XMLSchema#string

Evangelos Kiskinis

http://www.w3.org/2001/XMLSchema#string

Kevin Eggan

http://www.w3.org/2001/XMLSchema#string

Shila Mekhoubad

http://www.w3.org/2001/XMLSchema#string

P2860

X-inactivation profile reveals extensive variability in X-linked gene expression in females

Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

HPRT-APRT-deficient mice are not a model for lesch-nyhan syndrome

Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons

Somatic coding mutations in human induced pluripotent stem cells

A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells

Variations of X chromosome inactivation occur in early passages of female human embryonic stem cells

Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs.

Female human iPSCs retain an inactive X chromosome.

P304

595-609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.STEM.2012.02.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Meissner

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224912634

http://www.w3.org/2001/XMLSchema#string

P698

22560080

http://www.w3.org/2001/XMLSchema#string

P932

3603710

http://www.w3.org/2001/XMLSchema#string